Labcorp’s third purchase of BioReference assets since 2024 would add more than 80 patient service centers and a prostate cancer test to its diagnostics business for $722 million.
Labcorp and OPKO Health announced the agreement Oct. 15. BioReference Health, LLC is OPKO’s wholly owned subsidiary. The portfolio adds more than 80 patient service centers and BioReference’s proprietary 4Kscore Test, alongside selected operating assets and testing lines in clinical diagnostics, women’s health, urology and corrections.
Labcorp will pay $722 million in cash at closing, with the amount subject to an upward or downward adjustment based on revenue from the transferred businesses at that time. OPKO may receive as much as $150 million more under an earnout tied to 4Kscore revenue. Labcorp forecasts the acquired business will produce about $250 million in revenue in its first year after closing.
The U.S. Food and Drug Administration (FDA) approved 4Kscore in 2021 as a tool to inform prostate-biopsy decisions and assess the likelihood of aggressive prostate cancer. The FDA says a biopsy is needed to diagnose cancer. Reuters reported that 4Kscore generated $27.1 million in revenue in 2025.
OPKO announced Sept. 16, 2024, that Labcorp had completed a $237.5 million purchase of clinical diagnostics and reproductive and women’s health testing assets outside New York and New Jersey. A second transaction closed Sept. 15, 2025, covering oncology and related clinical testing; Labcorp paid $192.5 million at closing, with up to $32.5 million more based on revenue from certain customer accounts.
OPKO Chairman and CEO Phillip Frost said the transaction would allow the company to redirect resources toward its biopharmaceutical business. Labcorp Diagnostics President Bryan Vaughn said the purchase is intended to widen patient and provider access to specialized testing.
The companies said they will continue to operate separately and keep services unchanged while regulatory approvals and other customary closing conditions are pending. They did not give an expected closing date.
